Benzinga · Oct 6, 2026
Jones Trading Maintains Buy on Opus Genetics, Raises Price Target to $17
Jones Trading maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $10 to $17.
IR
NASDAQ · IRD
Opus Genetics, Inc.
Healthcare · Biotechnology
$4.64
Down-$0.21 (-4.42%)
Updated Oct 13, 2026, 5:25 PM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 167.86M
- P/E ratio
- -2.65
- Dividend yield
- 0.00%
- 52-week range
- $1.70 – $7.07
- Volume
- 1.62M
- Avg. volume
- 528.52K
Price performance · IRD
IRD price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 12, 2026
IRD closed at $4.64 after 21 trading sessions, down 22.28% for the selected period.
- Last close
- $4.64
- Period change
- -22.28%
- Period low
- $4.38
- Period high
- $5.97
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 12, 2026 | $4.63 | $4.88 | $4.60 | $4.64 | 1.62M |
| Oct 9, 2026 | $4.46 | $4.74 | $4.45 | $4.65 | 1.26M |
| Oct 8, 2026 | $4.41 | $4.48 | $4.245 | $4.46 | 1.35M |
| Oct 7, 2026 | $4.35 | $4.66 | $4.25 | $4.41 | 1.84M |
| Oct 6, 2026 | $4.465 | $4.48 | $4.185 | $4.38 | 2.54M |
| Oct 5, 2026 | $4.57 | $4.64 | $4.34 | $4.38 | 2.54M |
| Oct 2, 2026 | $4.56 | $4.67 | $4.445 | $4.58 | 1.79M |
| Oct 1, 2026 | $4.89 | $4.91 | $4.51 | $4.51 | 1.87M |
| Sep 30, 2026 | $4.96 | $5.32 | $4.83 | $4.84 | 2.46M |
| Sep 29, 2026 | $5.07 | $5.15 | $4.80 | $4.955 | 1.53M |
| Sep 28, 2026 | $4.75 | $5.14 | $4.625 | $5.05 | 1.16M |
| Sep 25, 2026 | $4.89 | $4.93 | $4.70 | $4.76 | 1.24M |
| Sep 24, 2026 | $4.76 | $4.955 | $4.60 | $4.87 | 1.83M |
| Sep 23, 2026 | $5.14 | $5.155 | $4.645 | $4.83 | 3.06M |
| Sep 22, 2026 | $5.20 | $5.30 | $5.04 | $5.16 | 1.17M |
| Sep 21, 2026 | $5.17 | $5.55 | $5.17 | $5.22 | 1.98M |
| Sep 18, 2026 | $5.29 | $5.3387 | $5.11 | $5.18 | 5.54M |
| Sep 17, 2026 | $5.46 | $5.62 | $5.23 | $5.28 | 1.53M |
| Sep 16, 2026 | $5.80 | $5.80 | $5.345 | $5.41 | 2.34M |
| Sep 15, 2026 | $5.94 | $5.95 | $5.6708 | $5.82 | 1.99M |
| Sep 14, 2026 | $6.02 | $6.22 | $5.795 | $5.97 | 2.55M |
Latest IRD news
The latest Smart Investors Daily articles mentioning IRD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
IRD research
Overview
Company profile and research snapshot.
Company profile
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Jones Trading | Buy | — |
| Oct 2, 2026 | Chardan Capital | Buy | — |
| Sep 10, 2026 | Wedbush | Outperform | — |
| Sep 9, 2026 | Chardan Capital | Buy | — |
| Sep 9, 2026 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 4, 2026
Opus Genetics, Inc. (IRD) Presents at Euretina 2026 - Slideshow
2026-10-04. The following slide deck was published by Opus Genetics, Inc.
Yahoo · Sep 16, 2026
Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]
ChartMill · Sep 10, 2026
Unusual volume stocks are being observed in Thursday's session.
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
